Hyperglycemic Hyperosmolar State

Hyperglycemic Hyperosmolar State (HHS) is a life-threatening endocrine emergency defined by extreme hyperglycemia and profound hyperosmolality in the absence of significant ketoacidosis ^[1]D5. This condition represents a severe perturbation of the glucose-insulin axis, typically occurring when relative insulin deficiency is coupled with inadequate fluid intake, leading to massive osmotic diuresis and dehydration ^[1]D5. While historically associated with type 2 diabetes mellitus, HHS is increasingly recognized across a spectrum of hyperglycemic presentations, including pediatric populations and patients with acute viral stressors ^[2]B3b[3]D5.

Synonyms and Abbreviations

• HHS: Hyperglycemic Hyperosmolar State
• HONK: Hyperglycemic Hyperosmolar Non-ketotic Coma (historical)
• HHNS: Hyperglycemic Hyperosmolar Non-ketotic State
• Mixed Presentation: Concurrent features of DKA and HHS

Classification and Variants

Clinical classification depends on the biochemical signature of the endocrine crisis, specifically the degree of ketosis versus the severity of hyperosmolality. In pediatric populations, pure HHS is rare, accounting for approximately 0.8% of hyperglycemic emergencies, whereas a mixed DKA-HHS presentation occurs in 13.8% of cases ^[2]B3b. Recognition of the specific variant is critical because hyperosmolar events carry a 3.7-fold greater odds of complications compared to isolated diabetic ketoacidosis ^[2]B3b.

Clinical Significance

HHS is a critical endocrine emergency with potentially devastating neurologic manifestations that may be fatal if left untreated ^[1]D5. Early diagnosis is essential but remains challenging due to a lack of objective diagnostic tools and the heterogeneity of presentation, particularly when triggered by acute stressors like COVID-19 ^[1]D5[3]D5. Patients with hyperosmolarity experience altered mental status more frequently than those with simple DKA ^[2]B3b.

Pearl: Always calculate the effective osmolality in hyperglycemic patients with altered mental status, as hyperosmolar states carry a significantly higher risk of complications than ketoacidosis alone ^[2]B3b.

The transition from compensated hyperglycemia to a hyperosmolar crisis is driven by a critical imbalance between insulin availability and the surge of counter-regulatory hormones, specifically glucagon, catecholamines, cortisol, and growth hormone ^[4]A1c, ^[5]D5. While diabetic ketoacidosis (DKA) results from an absolute insulin deficiency, the pathogenesis of this state is defined by a relative insulin deficiency where residual pancreatic beta-cell function remains sufficient to inhibit lipolysis and prevent significant ketogenesis, but is inadequate to facilitate peripheral glucose utilization ^[5]D5, ^[8]D5.

The Hyperglycemic Cascade

The metabolic derangement follows a predictable sequence of hormonal failure and osmotic collapse:

1. Relative Insulin Deficiency: Low circulating insulin levels, often exacerbated by stressors, fail to suppress hepatic gluconeogenesis and glycogenolysis ^[4]A1c.
2. Counter-regulatory Surge: Increased levels of glucagon and cortisol stimulate hepatic glucose production while catecholamines impair peripheral glucose uptake in skeletal muscle ^[5]D5.
3. Osmotic Diuresis: As blood glucose exceeds the renal threshold (approximately 180 mg/dL), glucose acts as an osmotic diuretic, leading to the loss of water, sodium, potassium, and other electrolytes ^[4]A1c.
4. Severe Dehydration: Progressive fluid loss reduces the glomerular filtration rate (GFR), which in turn limits renal glucose excretion, creating a vicious cycle of escalating hyperglycemia and hyperosmolality ^[7]D5.
5. Hyperosmolar State: The resulting serum hyperosmolality (often >320 mOsm/kg) causes an intracellular-to-extracellular fluid shift, leading to profound cellular dehydration, particularly within the central nervous system ^[4]A1c.

The Absence of Ketosis

A defining biochemical signature is the relative lack of ketoacidosis. The concentration of insulin required to suppress lipolysis is significantly lower than the concentration required for glucose utilization ^[5]D5. In this state, the portal vein insulin levels are high enough to prevent the activation of hormone-sensitive lipase in adipose tissue, thereby limiting the delivery of free fatty acids to the liver for ketogenesis ^[5]D5, ^[8]D5. Consequently, patients typically present with a normal or only mildly elevated anion gap, despite extreme hyperglycemia ^[4]A1c.

Biochemical Signature and Electrolyte Shifts

The biochemical profile is characterized by extreme elevations in serum glucose, often exceeding 600 mg/dL (33.3 mmol/L), and a calculated serum osmolality greater than 320 mOsm/kg ^[4]A1c. Total body potassium and sodium are invariably depleted due to osmotic diuresis, even if serum levels appear normal or elevated due to hemoconcentration and insulin deficiency ^[4]A1c, ^[5]D5.

Mechanism Flowchart

Genetic and Pharmacological Modifiers

While typically associated with type 2 diabetes, specific genetic variants and pharmacological agents can lower the threshold for this metabolic collapse. For example, variants in the HNF1A gene, which are associated with maturity-onset diabetes of the young (MODY3), can predispose individuals to severe glycemic instability ^[6]C4. Furthermore, medications such as diazoxide , used to treat hyperinsulinemic hypoglycemia, can inadvertently trigger a hyperosmolar state by suppressing insulin secretion ^[6]C4.

Pearl: The hallmark of this condition is the preservation of just enough insulin to prevent the burning of fat (ketosis) but not enough to prevent the skyrocketing of sugar (hyperglycemia) ^[5]D5.

The incidence of hyperglycemic emergencies has shifted significantly over the last decade, with HHS demonstrating a steeper rise in population-based rates compared to diabetic ketoacidosis (DKA). While DKA remains more common in absolute numbers, HHS events in the United States increased by 16.5% in emergency departments and 6.3% in inpatient settings between 2009 and 2015 ^[14]B2c. This trend is mirrored internationally; in Mexico, HHS-related mortality increased by 128% in 2020 compared to 2017-2019 averages ^[12]B2c.

Demographic Distribution

HHS predominantly affects older adults with type 2 diabetes, though its emergence in pediatric populations is rising alongside obesity rates ^{[14]B2c[19]C4}.

• Age: The highest concentration of HHS events occurs in middle-aged adults (45-64 years), accounting for 47.5% of cases ^[14]B2c. In contrast, DKA is primarily a disease of young adults (18-44 years) ^[14]B2c.
• Diabetes Type: Approximately 88.1% of HHS events occur in patients with type 2 diabetes ^[14]B2c.
• Socioeconomic Status: Approximately 40% of hyperglycemic events occur in lower-income populations ^[14]B2c.
• Sex and Race: In patients with end-stage kidney disease (ESKD), women and Black patients are disproportionately affected by hyperglycemic crises ^[13]B2b.

Etiology and Precipitating Factors

Precipitating factors for HHS typically involve conditions that increase insulin resistance or cause profound dehydration. Infection remains a primary trigger, but iatrogenic and structural factors are increasingly recognized.

• Chronic Pancreatitis: Patients with chronic pancreatitis have a 5.0-fold higher risk for HHS compared to matched controls ^[9]B2b.
• Medications: Second-generation antipsychotics (SGAs) are strongly associated with HHS. olanzapine and clozapine are frequently implicated, with HHS patients on antipsychotics presenting with an average blood glucose of 1252.8 mg/dL ^[18]B3a.
• Immune Checkpoint Inhibitors: Novel therapies like cadonilimab can induce acute-onset insulin deficiency, progressing rapidly to HHS or DKA ^[20]D5.
• Renal Disease: In the ESKD population, the rate of hyperglycemic crises is 18.24 per 1,000 person-years ^[13]B2b. Risk is higher in smokers and those with a history of substance abuse ^[13]B2b.

Risk Factors for Adverse Outcomes

Mortality and morbidity in HHS are driven by the severity of the metabolic derangement and underlying comorbidities. In pediatric cohorts, maximum serum glucose and initial pH are the strongest predictors of death or prolonged ICU stay ^[11]B3b.

Implementation of intermittently scanned continuous glucose monitoring (isCGM) in insulin-treated type 2 diabetes has been shown to reduce acute diabetes-related hospitalizations (RR 0.37), suggesting that monitoring gaps are a modifiable risk factor ^[15]B2b.

Pearl: Corrected sodium, rather than measured sodium, should be used to assess the true free water deficit, as hypernatremia is present in over 95% of HHS cases when adjusted for hyperglycemia ^[10]B3b.

Symptoms typically evolve over several days to weeks, contrasting with the more rapid onset of diabetic ketoacidosis (DKA) ^[4]A1c. This protracted timeline allows for extreme elevations in plasma glucose, often exceeding 600 mg/dL, and serum osmolarity over 320 mmol/kg, leading to profound intracellular and extracellular dehydration ^[18]B3a. Patients frequently present with a history of poorly controlled diabetes mellitus or as a first-time diagnosis in 17.2% to 23.8% of cases ^[18]B3a.

Presenting Symptoms

The clinical picture is dominated by the effects of osmotic diuresis and the underlying precipitating event, such as infection (30-60% of cases) or myocardial infarction ^[18]B3a.

• Polyuria and Polydipsia: Initial symptoms resulting from glycosuria-induced osmotic diuresis.
• Volume Depletion: Weight loss, dry mucous membranes, decreased skin turgor, and tachycardia ^[4]A1c.
• Abdominal Pain: While more common in DKA, abdominal discomfort may indicate complications like pyogenic liver abscess or emphysematous pyelonephritis ^[22]C4[23]C4.
• Fever: Often present if infection is the trigger, though its absence does not rule out sepsis ^[23]C4.

Neurological Examination Findings

Neurological manifestations are a hallmark of the hyperosmolar state and correlate with the severity of hyperosmolality ^[1]D5[16]B3a. These deficits may mimic acute vascular events, leading to diagnostic confusion.

• Altered Sensorium: Ranges from mild lethargy to profound coma ^[1]D5.
• Stroke-like Deficits: Acute focal signs including hemiparesis or hemianopia (the most common focal finding at 73%) ^[16]B3a.
• Visual Disturbances: Visual hallucinations are frequently associated with focal EEG slowing (85% of cases) ^[16]B3a.
• Seizures: May present as focal or generalized activity ^[1]D5.

Phenotypic Variants

While classically distinct, HHS often overlaps with DKA, particularly in younger populations or those with specific triggers.

Red Flags and Atypical Presentations

Clinicians must maintain a high index of suspicion for life-threatening complications that manifest during the initial presentation or early treatment phase.

• Autonomic Instability: Arrhythmias or refractory hypotension despite fluid resuscitation ^[19]C4.
• Rhabdomyolysis : Muscle pain and tea-colored urine, often secondary to extreme hyperosmolality ^[19]C4.
• Persistent Hypernatremia without Thirst: May indicate secondary central diabetes insipidus (CDI), especially if polyuria persists after SGLT2 inhibitor discontinuation ^[21]C4.
• Stroke Mimicry: Focal deficits in HHS often resolve within 3 to 10 days (median 6 days) following glucose normalization, unlike true ischemic infarcts ^[16]B3a.

Pearl: Neurological deficits in HHS, including hemianopia and hemiparesis, are often metabolic rather than ischemic and typically resolve within 6 days of aggressive glucose and volume correction ^[16]B3a.

Establishing the diagnosis requires immediate biochemical confirmation of extreme hyperglycemia and hyperosmolality, often following the clinical presentation of altered mental status or severe dehydration. While the classic paradigm distinguishes between diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS), contemporary evidence indicates that 65.5% (114/174) of HHS cases present with concurrent DKA, necessitating a diagnostic approach that evaluates both hyperosmolality and acid-base status ^[10]B3b. The 2024 ADA consensus report emphasizes that these conditions exist on a spectrum of hyperglycemic crises rather than as isolated entities ^{[4]A1c[24]A1c}.

Laboratory Studies and Biochemical Signature

Initial workup must include a comprehensive metabolic panel, serum osmolality, and assessment for ketosis. The biochemical hallmark is a serum glucose > 600 mg/dL (often exceeding 1000 mg/dL) and an effective serum osmolality > 320 mOsm/kg ^[4]A1c[25]D5. In patients treated with antipsychotics, the average blood glucose at presentation is significantly higher for HHS (1252.8 mg/dL) compared to DKA (842.8 mg/dL) ^[18]B3a.

• Serum Osmolality: Effective serum osmolality is calculated as [2 × measured sodium (mEq/L)] + [glucose (mg/dL) / 18]. Recent data suggests that an effective serum osmolarity > 300 mOsm/L may be a more sensitive diagnostic criterion than the traditional 320 mOsm/L threshold ^[10]B3b.
• Sodium Correction: Measured sodium often appears low due to the osmotic shift of water. Corrected sodium better reflects the true free water deficit; hypernatremia based on corrected sodium is present in 95.4% of HHS cases ^[10]B3b.
• Acid-Base Status: Unlike pure DKA, the arterial pH in HHS is typically > 7.30 and serum bicarbonate is > 18 mEq/L, though these thresholds are frequently crossed in mixed presentations ^{[4]A1c[10]B3b}.
• Hemoglobin A1c: Levels average approximately 12% in HHS patients, reflecting prolonged antecedent hyperglycemia ^[18]B3a.

Diagnostic Algorithm

Localization and Imaging

Imaging is primarily utilized to identify precipitating factors or neurological complications rather than to diagnose the metabolic state itself.

• Neuroimaging (MRI/CT): Indicated for patients with focal neurological deficits or failure to improve mentally despite metabolic correction. MRI may show Dark White Matter (DWM), diffuse subcortical white matter hypointensity on T2/FLAIR sequences, which is highly associated with non-ketotic HHS and repetitive seizures ^[17]B3a.
• Abdominal Imaging: Radiographs or CT should be obtained if abdominal pain is present to rule out complications like emphysematous pyelonephritis (EPN), which can present with gas in the renal parenchyma and pelvis ^[22]C4.
• Chest Radiography: Routine screening for pneumonia, a common precipitant of HHS ^[4]A1c.

Dynamic Testing and Monitoring

Dynamic assessment involves the continuous monitoring of the glucose-lowering response and the resolution of hyperosmolality. A critical diagnostic challenge arises when patients fail to concentrate urine despite hypernatremia, which may indicate secondary central diabetes insipidus (CDI) ^[21]C4. If CDI is suspected, a water deprivation test may be required after the acute hyperglycemic phase has resolved and SGLT2 inhibitors (e.g., dapagliflozin ) have been discontinued for at least 48 hours ^[21]C4.

Pearl: Always calculate the corrected sodium and effective osmolality; a measured sodium within the "normal" range in the setting of extreme hyperglycemia actually represents a profound free water deficit ^[10]B3b.

Risk stratification follows the biochemical confirmation of hyperosmolality, as the severity of initial metabolic derangements directly dictates the intensity of surveillance and the likelihood of adverse outcomes ^[11]B3b. While mortality rates have diminished due to the application of evidence-based guidelines, the complexity of HHS, often involving extreme hyperglycemia and profound dehydration, requires immediate triage based on neurological status, renal function, and comorbid triggers ^[8]D5.

Predictors of Adverse Outcomes

Clinical outcomes in hyperglycemic crises are heavily influenced by the degree of physiological insult at presentation. In pediatric and adolescent populations, a multivariable model identifies maximum serum glucose, initial pH, and a diagnosis of type 2 diabetes as the strongest independent predictors of adverse outcomes, defined as death or intensive care unit (ICU) stays exceeding 48 hours ^[11]B3b. The predictive power of these factors is robust, with an area under the receiver operator characteristic curve (AUC) of 0.948 for composite adverse outcomes and 0.984 for mortality ^[11]B3b.

Adverse outcome rates have shown temporal variability, increasing from 1.5% (2010-2019) to 5.0% during the 2020-2021 period, likely reflecting the impact of concurrent infections such as COVID-19 ^[11]B3b. In youth, the combination of obesity, type 2 diabetes, and COVID-19 represents a particularly high-risk phenotype for severe HHS ^[26]C4.

Neurological Risk Stratification

Neurological manifestations serve as a primary indicator of severity and often mimic acute stroke. Nonketotic hyperglycemic hyperosmolar state (NKHHS) is associated with a spectrum of deficits that correlate with the degree of hyperglycemia ^[16]B3a.

• Hemianopia: The most common presentation (73%), typically seen in patients with a mean glucose of 529.4 mg/dL ^[16]B3a.
• Anterior Circulation Syndrome: Occurs in 26% of cases, significantly associated with older age (mean 69.5 years) and higher mean glucose levels (674.8 mg/dL) ^[16]B3a.
• Imaging Findings: Brain MRI is abnormal in 71% of symptomatic patients; subcortical hypointensities in T2-FLAIR sequences are characteristic ^[16]B3a.

While 78% of neurological symptoms resolve within a median of 6 days following glucose normalization, prompt identification is essential to prevent irreversible neuronal dysfunction ^[16]B3a.

Comorbid and Etiological Risk Factors

Secondary complications and underlying triggers significantly alter the risk profile. Severe, refractory hypernatremia (peaking at 162.3 mmol/L) may indicate underlying partial urinary tract obstruction, which impairs renal medullary concentrating ability and necessitates surgical intervention for resolution ^[27]C4. Furthermore, the emergence of immune checkpoint inhibitors (ICIs) has introduced new etiological risks; agents like cadonilimab can induce acute-onset type 1 diabetes, rapidly progressing to HHS or DKA ^[20]D5.

Controversies and Guideline Disagreement

Risk stratification is complicated by a lack of international consensus on diagnostic and severity thresholds, particularly regarding osmolality calculations ^[28]D5.

Pearl: Initial pH and maximum glucose are the most reliable predictors of mortality (AUC 0.984), and their severity should trigger immediate escalation to high-acuity monitoring ^[11]B3b.

Building upon the risk stratification and severity staging previously established, acute management of Hyperglycemic Hyperosmolar State (HHS) requires a time-critical, coordinated approach focused on aggressive volume expansion, gradual electrolyte correction, and controlled glycemic reduction. The ADA 2024 consensus report emphasizes that HHS carries a higher mortality risk than diabetic ketoacidosis (DKA) and requires more cautious fluid and insulin titration to avoid rapid osmotic shifts ^{[4]A1c[24]A1c}.

Step 1: Initial Assessment and Disposition

Clinicians must immediately determine the level of care based on the severity of hyperosmolality and comorbid stability.

• ICU Admission Criteria: Indicated for patients with an effective serum osmolarity > 320 mOsm/L, altered mental status, hemodynamic instability, or concurrent severe DKA ^{[4]A1c[10]B3b}.
• Diagnostic Refinement: While traditional criteria require a total serum osmolarity > 320 mOsm/L, an effective serum osmolarity > 300 mOsm/L is a more sensitive diagnostic threshold for identifying clinically significant HHS ^[10]B3b.
• Corrected Sodium: Management must be guided by sodium levels corrected for hyperglycemia; hypernatremia based on corrected sodium is present in 95.4% of HHS cases, reflecting the true free water deficit ^[10]B3b.

Step 2: Fluid Resuscitation

Fluid replacement is the most critical initial intervention to restore circulatory volume and improve end-organ perfusion.

1. Initial Bolus: Administer 0.9% sodium chloride (normal saline) at 15-20 mL/kg/h or 1-1.5 L during the first hour to stabilize blood pressure ^[4]A1c[32]D5.
2. Maintenance Phase: Subsequent fluid choice depends on the corrected serum sodium. If corrected sodium is normal or high, switch to 0.45% sodium chloride; if low, continue 0.9% sodium chloride at 250-500 mL/h ^[4]A1c.
3. Glucose Integration: When serum glucose reaches 300 mg/dL, transition to 5% dextrose with 0.45% sodium chloride to prevent hypoglycemia and allow continued insulin administration for osmolality correction ^[4]A1c.

Step 3: Potassium and Electrolyte Management

Insulin therapy will shift potassium intracellularly, risking fatal arrhythmias if not pre-emptively managed.

• Potassium Thresholds:
• If K+ < 3.3 mEq/L: Hold insulin; administer 20-30 mEq/h until K+ > 3.3 mEq/L ^[4]A1c.
• If K+ 3.3-5.2 mEq/L: Add 20-30 mEq of potassium to each liter of IV fluid to maintain serum levels between 4.0-5.0 mEq/L ^[4]A1c.
• If K+ > 5.2 mEq/L: Do not supplement; check levels every 2 hours ^[4]A1c.

Step 4: Insulin Therapy

Insulin should only be initiated after fluid resuscitation is underway and potassium is ≥ 3.3 mEq/L.

1. Regimen: Administer a continuous regular insulin infusion at 0.1 unit/kg/h, or a 0.1 unit/kg bolus followed by 0.1 unit/kg/h ^[4]A1c[5]D5.
2. Target Reduction: Aim for a glucose decrease of 50-70 mg/dL/h. If glucose does not fall by at least 50 mg/dL in the first hour, check fluid status; if adequate, increase insulin dose by hourly increments ^[4]A1c.
3. Subcutaneous Alternative: In mild to moderate cases where IV access or ICU resources are limited, subcutaneous rapid-acting insulin analogs may be considered, though IV remains the standard for severe HHS ^[4]A1c.

Step 5: Monitoring and Resolution

• Frequency: Monitor electrolytes, glucose, and venous pH every 2-4 hours; monitor vital signs and fluid balance hourly ^[4]A1c.
• Resolution Criteria: HHS is considered resolved when effective osmolality is < 310 mOsm/L, blood glucose is ≤ 250-300 mg/dL, and the patient has regained baseline mental status ^{[4]A1c[24]A1c}.

Controversies and Guideline Disagreement

Drug / Modality Comparison Table

What NOT to Do

• Do NOT initiate insulin if potassium is < 3.3 mEq/L, as this may precipitate cardiac arrest ^[4]A1c.
• Do NOT use bicarbonate therapy routinely; HHS patients typically do not have the severe acidemia seen in DKA, and bicarbonate may worsen hypokalemia ^[4]A1c[5]D5.
• Do NOT drop blood glucose faster than 70-100 mg/dL/h once the initial decline occurs, to minimize the risk of cerebral edema ^[4]A1c.

Pearl: Prioritize volume resuscitation over insulin; in HHS, the corrected sodium and effective osmolarity (target > 300 mOsm/L) are more accurate guides for fluid therapy than measured values ^{[10]B3b[24]A1c}.

Transitioning from acute resuscitation to long-term management requires a shift from rapid volume expansion to the restoration of physiologic insulin signaling and the mitigation of chronic metabolic derangements. The 2024 ADA consensus report emphasizes that the resolution of HHS is defined by a return to baseline mental status and a serum osmolality below 310 mOsm/kg ^{[4]A1c[24]A1c}. Once these targets are met, the management spine focuses on definitive glycemic control and the suppression of the counter-regulatory surge that precipitated the crisis.

Step 1: Transition to Subcutaneous Insulin Replacement

Transitioning from intravenous (IV) to subcutaneous (SC) insulin should occur only when the patient is alert, able to eat, and has achieved biochemical resolution. To prevent a recurrence of hyperglycemia, the SC insulin must be administered 2 to 4 hours before the IV infusion is discontinued ^[4]A1c.

• Insulin-Naive Patients: Initiate a basal-bolus regimen at a total daily dose (TDD) of 0.5 units/kg ^[4]A1c.
• Prior Insulin Users: Resume the pre-admission regimen, though adjustments are often necessary if the prior dose failed to prevent the crisis.
• Mild to Moderate Cases: In settings with limited intensive care resources, SC rapid-acting insulin analogs may be used as an alternative to IV infusion for uncomplicated cases, provided close monitoring is available ^[30]A1c.

Step 2: Suppression of Precipitating Factors and Comorbidities

Long-term stability requires identifying and suppressing the underlying triggers that disrupted the metabolic axis.

• Antipsychotic Management: Second-generation antipsychotics (SGAs), particularly olanzapine and clozapine , are strongly associated with HHS development ^[18]B3a. In a systematic review of 151 cases, olanzapine was linked to the highest number of hyperglycemic emergencies ^[18]B3a. Clinicians must monitor metabolic risk factors or consider switching to agents with lower metabolic impact.
• Immune Checkpoint Inhibitors (ICIs): Patients receiving ICIs like cadonilimab can develop acute-onset insulin deficiency (ICI-T1DM), which often presents as HHS ^[20]D5 (5). These patients require lifelong insulin replacement as the pancreatic beta-cell suppression is typically irreversible.
• SGLT2 Inhibitor Caution: While dapagliflozin is effective for glucose control, it must be discontinued if central diabetes insipidus (CDI) is suspected, as it can accelerate polyuria and mask diagnostic urine osmolality patterns ^[21]C4 (4).

Step 3: Definitive Treatment of Structural and Secondary Lesions

In cases where HHS is exacerbated by secondary physiological stressors, definitive surgical or medical intervention is required to normalize the metabolic state.

• Urological Obstruction: Partial urinary tract obstruction (e.g., benign prostatic hyperplasia or bladder calculi) can induce refractory hypernatremia by impairing renal medullary concentrating ability ^[27]C4 (4). Definitive surgical relief of the obstruction, such as transurethral holmium laser enucleation, has been shown to rapidly normalize serum sodium from peaks as high as 162.3 mmol/L to 139.7 mmol/L ^[27]C4.
• Neurological Monitoring: Patients presenting with focal deficits or seizures should be evaluated for "Dark White Matter" (DWM) on MRI, subcortical T2/FLAIR hypointensities ^[17]B3a. While these stroke-like deficits often resolve within 6 days (IQR 3-10) following glucose normalization, their presence necessitates aggressive metabolic suppression to prevent permanent neuronal dysfunction ^[16]B3a.

Step 4: Monitoring and Titration in Special Populations

Long-term titration must account for altered pharmacokinetics and monitoring challenges in specific cohorts.

• End-Stage Kidney Disease (ESKD): Patients with ESKD have a lower risk of hyperglycemic crises compared to hypoglycemic crises (18.24 vs 53.64 per 1,000 person-years) ^[13]B2b. However, the risk of HHS is significantly higher in younger patients, women, and those with a history of smoking or substance abuse ^[13]B2b.
• Obesity: Standard monitoring may be less reliable in obese patients. Microdialysis studies show that the recovery of glucose in interstitial fluid correlates with BMI (r = 0.55), with significantly lower recovery in obese patients (55%) compared to lean patients (91%) ^[33]B2b.

Controversies and Guideline Disagreement

Pearl: Transition to subcutaneous insulin only after serum osmolality drops below 310 mOsm/kg and mental status normalizes; ensure a 2 to 4 hour insulin overlap to prevent rebound hyperosmolarity ^{[4]A1c[24]A1c}.

Management strategies for hyperglycemic crises have transitioned from high-dose insulin protocols toward a more nuanced focus on aggressive fluid resuscitation and the prevention of iatrogenic complications. While the core pathophysiology of relative insulin deficiency remains constant, the therapeutic landscape has been refined by a deeper understanding of the risks associated with rapid osmotic shifts and the specific needs of vulnerable populations ^[34]D5.

The Shift Toward Standardized Protocols

For decades, the management of hyperglycemic emergencies was characterized by significant variability in insulin dosing and fluid selection. The American Diabetes Association (ADA) published a landmark consensus report 15 years ago that established the modern framework for treating DKA and HHS ^[24]A1c. This framework prioritized intravenous (IV) insulin as the gold standard, though recent updates in June 2024 have introduced revised criteria for diagnosis and resolution to better reflect real-world clinical outcomes ^[24]A1c.

Key historical shifts in treatment philosophy include:

• Insulin Dosing: Transition from intermittent high-dose boluses to continuous low-dose IV infusions to minimize the risk of hypoglycemia and hypokalemia ^[34]D5.
• Fluid Resuscitation: Recognition that aggressive volume expansion is the primary intervention in HHS, often preceding insulin therapy to stabilize hemodynamics and improve renal perfusion ^[34]D5.
• Subcutaneous Alternatives: In resource-limited settings or during crises like the COVID-19 pandemic, evidence has emerged supporting subcutaneous insulin for mild to moderate cases when intensive care unit (ICU) resources are unavailable ^[30]A1c.

Evolution in Specialized Contexts

The emergence of novel therapies has necessitated the adaptation of traditional treatment protocols. The introduction of immune checkpoint inhibitors (ICIs), such as cadonilimab , has created a new class of treatment-induced hyperglycemic emergencies ^[20]D5. These cases often present with rapid beta-cell failure, requiring clinicians to apply HHS/DKA protocols to patients who may have had no prior history of diabetes ^[20]D5. Furthermore, the management of patients with end-stage kidney disease (ESKD) has evolved to account for their significantly higher risk of hypoglycemic crises, which occur threefold more frequently than hyperglycemic crises in this population (53.64 vs 18.24 per 1,000 person-years) ^[13]B2b.

Landmark Observations in Mortality and Risk

Historical data have consistently demonstrated a higher mortality rate for HHS (approximately 15%) compared to DKA (< 1%) ^[34]D5. This disparity has driven the evolution of risk stratification tools. Modern practice now emphasizes identifying sociodemographic and clinical predictors of recurrence. For instance, a history of prior hyperglycemic crises is associated with a markedly increased risk of future events (IRR 17.51 for type 2 diabetes) ^[38]B3b.

Controversies and Guideline Disagreement

Pearl: The historical transition from high-dose insulin to aggressive fluid-first resuscitation reflects the clinical priority of correcting the profound 10-12 liter water deficit characteristic of HHS before addressing hyperglycemia ^[34]D5.

Genetic predispositions and syndromic associations significantly influence the risk and severity of Hyperglycemic Hyperosmolar State (HHS), particularly when metabolic stressors perturb multiple endocrine axes. While HHS is classically associated with type 2 diabetes, it increasingly occurs in pediatric populations with complex genetic backgrounds or as a complication of pharmacotherapy for other endocrine disorders ^[11]B3b, ^[6]C4.

Genetic and Syndromic Associations

Inherited syndromes that affect neurodevelopment or metabolic regulation can predispose patients to extreme hyperglycemic crises. Cases of HHS have been documented in children with Joubert syndrome, where patients may present with extreme glucose elevations (e.g., 115 mmol/L) and severe dehydration ^[43]C4. The intersection of obesity and type 2 diabetes in adolescents, often linked to polygenic or syndromic factors, represents a high-risk group for severe metabolic decompensation, especially when triggered by acute infections like COVID-19 ^[26]C4.

Pharmacogenetic Risks and Co-Axis Effects

Therapeutic interventions for other endocrine axes can inadvertently precipitate HHS. A critical example involves the use of diazoxide for congenital hyperinsulinism. Novel variants in the HNF1A gene can cause extreme hypersensitivity to diazoxide , where even conventional doses (5 mg/kg/day) or low doses (3 mg/kg/day) may trigger rapid transitions from hypoglycemia to severe hyperglycemia ^[6]C4. Clinicians must monitor for HHS when initiating diazoxide in patients with HNF1A mutations, as the resulting metabolic shift can be mutation-specific and require doses as low as 0.7 mg/kg/day to maintain euglycemia ^[6]C4.

Neurological and Systemic Axis Perturbations

The profound hyperosmolality of HHS frequently manifests as acute neurological dysfunction, which may mimic primary cerebrovascular events. These "stroke-like" deficits are often metabolic rather than structural in origin ^[16]B3a.

• Neurological Findings: Hemianopia is the most common presentation (73%), followed by anterior circulation syndromes (26%) ^[16]B3a.
• Imaging Signatures: T2-FLAIR MRI sequences frequently show subcortical hypointensities, while cortical DWI hyperintensities occur in 64% of cases ^[16]B3a.
• Resolution: Symptoms typically resolve within 6 days (IQR 3-10) following aggressive glucose normalization ^[16]B3a.

Risk Factors for Adverse Outcomes

In pediatric and adolescent populations, the presence of type 2 diabetes is a primary driver of morbidity. A multivariable model identified maximum serum glucose, initial pH, and a diagnosis of type 2 diabetes as the strongest predictors of adverse outcomes (AUC 0.948) ^[11]B3b.

Pearl: In patients with HNF1A-related hyperinsulinism, diazoxide can precipitate HHS at standard doses; initiate therapy at low doses and monitor for rapid glycemic escalation ^[6]C4.

Chronic metabolic derangements following an episode of hyperglycemic hyperosmolar state (HHS) necessitate rigorous surveillance for both acute multi-organ failure and long-term vascular or endocrine sequelae. While the immediate focus remains on fluid resuscitation and insulin therapy, the transition to long-term management must address the high risk of recurrence and the systemic damage incurred during the hyperosmolar crisis.

Acute and Autonomic Complications

The extreme hyperosmolality and dehydration characteristic of HHS predispose patients to severe multi-organ dysfunction. In pediatric and adolescent populations, early recognition of hyperosmolality is critical to prevent complications such as arrhythmia, rhabdomyolysis , and acute kidney injury (AKI) ^[19]C4. Severe cases may require renal replacement therapy to manage AKI ^[19]C4. Furthermore, the metabolic stress of HHS can trigger or occur concurrently with acute pancreatitis, which complicates the clinical course and increases the risk of subsequent glycemic instability ^[9]B2b[19]C4.

Respiratory and Hospital-Acquired Monitoring

Patients with HHS often require intensive care monitoring due to the risk of respiratory failure or altered consciousness. While intravenous insulin remains the standard of choice, subcutaneous insulin may be considered in resource-limited settings for uncomplicated cases to prioritize ICU capacity ^[30]A1c. Monitoring for hospital-acquired complications is essential, as the median length of stay for acute diabetes-related hospitalizations is approximately 3 to 4 days ^[15]B2b.

Long-term Sequelae and Mortality Risk

Survivors of HHS face significantly elevated long-term mortality and morbidity. Patients with comorbid conditions like chronic pancreatitis have a 5.0-fold higher risk for HHS and a 2.43-fold higher risk for death compared to those without pancreatic inflammation ^[9]B2b. Cumulative survival rates in these high-risk populations decline from 98.4% at 1 year to 78.7% at 10 years ^[9]B2b.

Preventive Strategies and Technology

The implementation of intermittently scanned continuous glucose monitoring ( isCGM ) has demonstrated significant utility in reducing long-term sequelae. In insulin-treated type 2 diabetes, isCGM use is associated with a reduction in diabetes-related hospitalization rates from 74.6 to 27.5 per 10,000 person-years ^[15]B2b. This technology also correlates with a decrease in mean HbA1c from 8.09% to 7.65%, potentially mitigating the risk of future hyperglycemic emergencies ^[15]B2b.

Pearl: Early recognition of hyperosmolality is the primary determinant of outcome; inadequate fluid rehydration in the initial treatment phase is a major contributor to rhabdomyolysis and multi-organ failure ^[19]C4.

The clinical trajectory of HHS is characterized by a higher mortality rate than diabetic ketoacidosis, often due to the advanced age of patients and the severity of underlying precipitating illnesses ^[4]A1c. While inpatient admission rates for HHS increased significantly between 2009 and 2015 (APC 6.3%), the prognosis remains heavily dependent on the speed of metabolic correction and the management of concurrent complications ^[14]B2c.

Prognostic Determinants and Mortality

Mortality in HHS is frequently driven by the primary precipitating event, such as sepsis or myocardial infarction, rather than the metabolic derangement alone ^[4]A1c. In specific high-risk cohorts, such as patients with chronic pancreatitis, the 10-year cumulative survival rate is significantly lower at 78.7% compared to 93.6% in matched diabetic controls (HR 2.43) ^[9]B2b.

• Neurological Recovery: Stroke-like deficits, including hemianopia (73%) and anterior circulation syndromes (26%), typically resolve within 6 days (IQR 3-10) following glucose normalization ^[16]B3a.
• Fatalities in Drug-Induced Cases: In cases associated with atypical antipsychotics, fatalities have been documented, including those involving olanzapine ^[18]B3a.
• Renal Factors: Persistent hypernatremia (e.g., peaks of 162.3 mmol/L) may indicate secondary complications like urinary tract obstruction, which requires surgical resolution to normalize sodium levels ^[27]C4.

Natural History and Recurrence

Without aggressive intervention, the natural history of HHS progresses toward profound dehydration, coma, and death ^[1]D5. The condition primarily affects middle-aged adults (47.5% aged 45-64) and those with type 2 diabetes (88.1%) ^[14]B2c. Emerging triggers, such as immune checkpoint inhibitors (e.g., cadonilimab ), can cause rapid progression from new-onset diabetes to HHS, necessitating lifelong insulin therapy ^[20]D5.

Prevention and Screening

Prevention strategies focus on early recognition of rising glucose levels and the management of modifiable risk factors ^[4]A1c. The 2024 ADA consensus report emphasizes that approximately 40% of hyperglycemic crises occur in lower-income populations, suggesting that socioeconomic barriers to medication adherence are a primary target for prevention ^{[14]B2c[24]A1c}.

• Patient Education: Instruction on "sick day rules," including frequent glucose monitoring and maintaining hydration during acute illness ^[4]A1c.
• Medication Vigilance: Routine metabolic monitoring for patients prescribed second-generation antipsychotics, particularly olanzapine and clozapine , which are associated with extreme hyperglycemia (mean glucose 1252.8 mg/dL in HHS cases) ^[18]B3a.
• Clinical Monitoring: Early investigation of urological symptoms in elderly males to prevent obstructive-induced electrolyte crises ^[27]C4.

Pearl: Neurological deficits in HHS often mimic acute stroke but typically resolve within 3 to 10 days of metabolic correction, provided subcortical hypointensities on T2-FLAIR MRI are identified early ^[16]B3a.

Management of hyperosmolar emergencies must be tailored to the physiological shifts of specific patient groups, as the standard protocols for fluid and insulin titration may require adjustment to account for age-related frailty or developmental risks. While the core principles of aggressive rehydration and electrolyte correction remain, the risk profile for complications like cerebral edema or multi-organ failure varies significantly across the lifespan ^[19]C4[25]D5.

Pediatrics and Adolescents

Pediatric cases are increasingly linked to the rise in adolescent obesity and type 2 diabetes, with an incidence of 2% reported in a United States multicenter study ^[19]C4. Diagnosis is frequently complicated by a mixed clinical picture where features of hyperosmolality and ketoacidosis coexist, leading to initial misdiagnosis as diabetic ketoacidosis (DKA) in 5 out of 9 cases in one series ^[19]C4.

• Fluid Management: Early recognition of hyperosmolality is essential to initiate more vigorous fluid replacement than is standard for DKA ^[19]C4.
• Insulin Delivery: While intravenous infusion is the standard of care, subcutaneous insulin may be considered for uncomplicated mild to moderate DKA/HHS in resource-limited settings or during pandemic-related ICU constraints ^[30]A1c.
• Complications: Pediatric patients are at risk for severe sequelae including arrhythmia, acute kidney injury requiring renal replacement therapy, rhabdomyolysis , and acute pancreatitis ^[19]C4.

Elderly Patients

Elderly individuals represent the classic demographic for this condition, often presenting with type 2 diabetes and significant comorbidities ^[25]D5[46]D5. Management is complicated by age-related physiological changes, sarcopenia, and varying levels of cognitive or mobility impairment ^[46]D5.

• Diagnostic Considerations: Elderly males presenting with unexplained, refractory hypernatremia (e.g., serum sodium peaking at 162.3 mmol/L) should be evaluated for partial urinary tract obstruction, such as benign prostatic hyperplasia or bladder calculi, which can impair renal medullary concentrating ability ^[27]C4.
• Neurological Findings: "Diabetic striatopathy," characterized by dyskinesias and basal ganglia hyperintensities on neuroimaging, is most commonly reported in elderly females with hyperosmolar states ^[44]C4.
• Risk Profile: This population faces an elevated risk of cardiovascular disease, cancer, and mortality, necessitating a personalized strategy that balances aggressive crisis management with the risks of severe hypoglycemia ^[46]D5.

Perioperative and Acute Stress

Inpatient management during the perioperative period or acute illness (such as COVID-19 ) requires integration of evolving technologies like continuous glucose monitoring and computer-guided insulin dosing software to improve safety and glycemic control ^[45]D5. The choice of crystalloid, comparing 0.9% saline to buffered solutions like Lactated Ringer's or Hartmann's, remains a critical decision point for clinicians managing large-volume resuscitation in these high-stress states ^[32]D5.

Pearl: In pediatric patients, always calculate the effective osmolality early, as over half of cases may initially mask as simple DKA, leading to under-resuscitation ^[19]C4.